Revolution Medicines’ Rasonque Wins CHMP Recommendation for EU Approval in Pancreatic Cancer
Revolution Medicines’ Rasonque received a positive CHMP opinion recommending EU authorization for adults with metastatic pancreatic adenocarcinoma following prior systemic therapy. European Commission approval remains pending; the drug reduced death risk by 60% versus chemotherapy in the Phase 3 trial. Disclaimer: This